Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 24

Trial Status

Completed1
Terminated1
Other2

Role Distribution

Principal Investigator4
PI Rate100%

Activity Timeline

Clinical Trials (4)

NCT03498612Phase 2Terminated
Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
Follicular LymphomaIndolent B-Cell Non-Hodgkin LymphomaMarginal Zone Lymphoma
PrincipalinvestigatorStart date: 2018-07-09
NCT02339922Phase 2Active Not Recruiting
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
Chronic Lymphocytic LeukemiaFollicular LymphomaLymphoplasmacytic Lymphoma+6 more
PrincipalinvestigatorStart date: 2016-05-19
NCT01703949Phase 2Active Not Recruiting
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma
Recurrent Hodgkin LymphomaRecurrent Non-Hodgkin LymphomaRefractory Hodgkin Lymphoma+1 more
PrincipalinvestigatorStart date: 2013-03-20
NCT02207062Phase 2Completed
Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma
Recurrent Transformed B-Cell Non-Hodgkin LymphomaRefractory Transformed B-Cell Non-Hodgkin Lymphoma
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Jae Park, MD

Memorial Sloan Kettering Cancer Center

Related
17 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellMarginal Zone LymphomaWaldenstrom Macroglobulinemia
Similarity Score6%

Hagop Youssoufian, MD

Verastem, Inc.

Related
20 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, FollicularMarginal Zone Lymphoma
Similarity Score6%

Michael B Gill

Power Life Sciences Inc.

Related
105 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, FollicularLymphoma, Mantle-Cell
Similarity Score6%

Mary Horowitz, MD

Center for International Blood and Marrow Transplant Research

Related
24 trials

Shared therapeutic areas:

Lymphoma, FollicularLeukemia, Lymphocytic, Chronic, B-Cell
Similarity Score4%

Agostino Tafuri

AOU Sant'Andrea

Related
1 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-Cell
Similarity Score2%

Laura Nocilli

Ospedale Papardo

Related
1 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-Cell
Similarity Score2%

Vincenzo Fraticelli

Responsible Research Hospital

Related
1 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-Cell
Similarity Score2%

Roberta Murru

Ospedale Oncologico" A. Businco" - ARNAS "G. Brotzu"

Related
1 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-Cell
Similarity Score2%

Roberto Hernández Martín, MD

Hospital Virgen de la Concha

Related
2 trials

Shared therapeutic areas:

Lymphoma, Mantle-Cell
Similarity Score2%

Luca Laurenti

Policlinico Universitario Gemelli IRCCS

Related
1 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-Cell
Similarity Score2%

Publications (0)

No publications found for this investigator.

Clinical Trials (4)

Showing 4 of 4 trials

NCT03498612Phase 2PrincipalInvestigator

Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

Follicular LymphomaIndolent B-Cell Non-Hodgkin LymphomaMarginal Zone Lymphoma
Terminated
NCT02339922Phase 2PrincipalInvestigator

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

Chronic Lymphocytic LeukemiaFollicular LymphomaLymphoplasmacytic Lymphoma+6 more
Active Not Recruiting
NCT01703949Phase 2PrincipalInvestigator

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

Recurrent Hodgkin LymphomaRecurrent Non-Hodgkin LymphomaRefractory Hodgkin Lymphoma+1 more
Active Not Recruiting
NCT02207062Phase 2PrincipalInvestigator

Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma

Recurrent Transformed B-Cell Non-Hodgkin LymphomaRefractory Transformed B-Cell Non-Hodgkin Lymphoma
Completed

All 4 trials loaded